[
  {
    "ts": null,
    "headline": "Why Eli Lilly Is The Lion's Share Of My Portfolio",
    "summary": "Eli Lillyâs new GLP-1 drug and diversified R&D pipeline could drive healthcare sector inflows and deliver over 40% upside. See here for more on LLY stock.",
    "url": "https://finnhub.io/api/news?id=4b2e08e689137e71c97ab431702f6dcf0001bc5b62f8f2eb7e81ef7ca39691ae",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759447570,
      "headline": "Why Eli Lilly Is The Lion's Share Of My Portfolio",
      "id": 136959244,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1340927829/image_1340927829.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lillyâs new GLP-1 drug and diversified R&D pipeline could drive healthcare sector inflows and deliver over 40% upside. See here for more on LLY stock.",
      "url": "https://finnhub.io/api/news?id=4b2e08e689137e71c97ab431702f6dcf0001bc5b62f8f2eb7e81ef7ca39691ae"
    }
  },
  {
    "ts": null,
    "headline": "Centene, QuidelOrtho, iRhythm, and Bio-Techne Shares Skyrocket, What You Need To Know",
    "summary": "A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations.",
    "url": "https://finnhub.io/api/news?id=fdc898911eaa47fc69ce2e4905bc3d6558c4e347ad96247869e9764a01cb4818",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759434650,
      "headline": "Centene, QuidelOrtho, iRhythm, and Bio-Techne Shares Skyrocket, What You Need To Know",
      "id": 136959912,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations.",
      "url": "https://finnhub.io/api/news?id=fdc898911eaa47fc69ce2e4905bc3d6558c4e347ad96247869e9764a01cb4818"
    }
  },
  {
    "ts": null,
    "headline": "agilon health, Tandem Diabetes, NeoGenomics, Hims & Hers Health, and Oscar Health Stocks Trade Up, What You Need To Know",
    "summary": "A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations.",
    "url": "https://finnhub.io/api/news?id=84c09a7b6806ce9ccb22a9fee3d22cd6b1be219c178c1e057faf5cf7625bb63b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759434649,
      "headline": "agilon health, Tandem Diabetes, NeoGenomics, Hims & Hers Health, and Oscar Health Stocks Trade Up, What You Need To Know",
      "id": 136959913,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations.",
      "url": "https://finnhub.io/api/news?id=84c09a7b6806ce9ccb22a9fee3d22cd6b1be219c178c1e057faf5cf7625bb63b"
    }
  },
  {
    "ts": null,
    "headline": "Buy Novo Nordisk Stock as Health Names Return to Favor, Analyst Says",
    "summary": "HSBC made the call as it listed the pharma stocks it sees as best positioned to play a recovery in the sector.",
    "url": "https://finnhub.io/api/news?id=71f2be6d42a57c4dd8e4ded6c5201d00a607f13283c5cf8076e9af35ae5b3c5c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759423920,
      "headline": "Buy Novo Nordisk Stock as Health Names Return to Favor, Analyst Says",
      "id": 136959914,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "HSBC made the call as it listed the pharma stocks it sees as best positioned to play a recovery in the sector.",
      "url": "https://finnhub.io/api/news?id=71f2be6d42a57c4dd8e4ded6c5201d00a607f13283c5cf8076e9af35ae5b3c5c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Valuation: Assessing Growth Potential After U.S. Drug Pricing Policy Shift and Fresh Approvals",
    "summary": "Eli Lilly (LLY) shares climbed sharply after the White House announced a new platform for Americans to buy prescription drugs directly from manufacturers at a discount. This move removed uncertainty around future drug pricing policy. See our latest analysis for Eli Lilly. This surge in Eli Lilly's share price comes on the heels of fresh product approvals and major expansion plans, such as its $6.5 billion facility in Texas and new San Diego innovation hub, painting a picture of a company...",
    "url": "https://finnhub.io/api/news?id=95d9b66fbcb96d6e5d440a3709511b369f9505f332313738cbd4f692a305b9c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759419732,
      "headline": "Eli Lilly (LLY) Valuation: Assessing Growth Potential After U.S. Drug Pricing Policy Shift and Fresh Approvals",
      "id": 136959915,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) shares climbed sharply after the White House announced a new platform for Americans to buy prescription drugs directly from manufacturers at a discount. This move removed uncertainty around future drug pricing policy. See our latest analysis for Eli Lilly. This surge in Eli Lilly's share price comes on the heels of fresh product approvals and major expansion plans, such as its $6.5 billion facility in Texas and new San Diego innovation hub, painting a picture of a company...",
      "url": "https://finnhub.io/api/news?id=95d9b66fbcb96d6e5d440a3709511b369f9505f332313738cbd4f692a305b9c5"
    }
  },
  {
    "ts": null,
    "headline": "Alexandria Real Estate Equities (ARE): Assessing Valuation Following Lilly Gateway Labs Partnership in San Diego",
    "summary": "Alexandria Real Estate Equities (ARE) is teaming up with Eli Lilly to launch Lilly Gateway Labs in San Diego, expanding its footprint in the life sciences real estate sector. This move further strengthens Alexandria’s connection to the region's thriving biotech ecosystem. See our latest analysis for Alexandria Real Estate Equities. Alexandria’s collaboration with Lilly comes at a time when its stock has faced challenges, with its latest share price at $83.46 and a one-year total shareholder...",
    "url": "https://finnhub.io/api/news?id=88d4f0f3d18aedb5494fe15af2170acb8de6f6dc9878d6b34046ab1b2b9f3779",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759417127,
      "headline": "Alexandria Real Estate Equities (ARE): Assessing Valuation Following Lilly Gateway Labs Partnership in San Diego",
      "id": 136959916,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Alexandria Real Estate Equities (ARE) is teaming up with Eli Lilly to launch Lilly Gateway Labs in San Diego, expanding its footprint in the life sciences real estate sector. This move further strengthens Alexandria’s connection to the region's thriving biotech ecosystem. See our latest analysis for Alexandria Real Estate Equities. Alexandria’s collaboration with Lilly comes at a time when its stock has faced challenges, with its latest share price at $83.46 and a one-year total shareholder...",
      "url": "https://finnhub.io/api/news?id=88d4f0f3d18aedb5494fe15af2170acb8de6f6dc9878d6b34046ab1b2b9f3779"
    }
  },
  {
    "ts": null,
    "headline": "LEXX: Biodistribution Study Results",
    "summary": "By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT As we step into fall, Lexaria Bioscience Corporation (NASDAQ:LEXX) continues to work on multiple GLP-1 trials. Most notably, it reported the last patient-last visit for the Phase Ib study designated GLP-1-H24-4 and reported data from its rodent biodistribution study. It also closed a $4.0 million capital raise earlier this",
    "url": "https://finnhub.io/api/news?id=f1eefdbee0d64aa85b27048ed6b95a9f1073358b9f2038592146ef2390d7899a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759413840,
      "headline": "LEXX: Biodistribution Study Results",
      "id": 136959917,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT As we step into fall, Lexaria Bioscience Corporation (NASDAQ:LEXX) continues to work on multiple GLP-1 trials. Most notably, it reported the last patient-last visit for the Phase Ib study designated GLP-1-H24-4 and reported data from its rodent biodistribution study. It also closed a $4.0 million capital raise earlier this",
      "url": "https://finnhub.io/api/news?id=f1eefdbee0d64aa85b27048ed6b95a9f1073358b9f2038592146ef2390d7899a"
    }
  },
  {
    "ts": null,
    "headline": "Market Chatter: White House Asking Companies to Make Deals Ahead of Midterm Elections",
    "summary": "The White House is asking pharmaceutical and other companies for deals meant to boost the popularity",
    "url": "https://finnhub.io/api/news?id=0c09b61ff324ec415d02050cac9142a892427322cfacc6af1323f139ae85e712",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759405900,
      "headline": "Market Chatter: White House Asking Companies to Make Deals Ahead of Midterm Elections",
      "id": 136955299,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The White House is asking pharmaceutical and other companies for deals meant to boost the popularity",
      "url": "https://finnhub.io/api/news?id=0c09b61ff324ec415d02050cac9142a892427322cfacc6af1323f139ae85e712"
    }
  },
  {
    "ts": null,
    "headline": "Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Thursday; Advanced Micro Devices, Opendoor Technologies to Advance",
    "summary": "The most-talked-about stocks in the Reddit subforum Wallstreetbets were mostly higher hours before T",
    "url": "https://finnhub.io/api/news?id=316789e1363ab4dc93c8cf3c22a7c233a71900903939f2a502ee8ba246b1e4dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759402048,
      "headline": "Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Thursday; Advanced Micro Devices, Opendoor Technologies to Advance",
      "id": 136955188,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The most-talked-about stocks in the Reddit subforum Wallstreetbets were mostly higher hours before T",
      "url": "https://finnhub.io/api/news?id=316789e1363ab4dc93c8cf3c22a7c233a71900903939f2a502ee8ba246b1e4dd"
    }
  },
  {
    "ts": null,
    "headline": "3 Blue Chip Stocks That Have Soared 380% (and Higher) Over the Past 5 Years",
    "summary": "By investing in quality growth stocks, you can put yourself in an excellent position to earn a great return.",
    "url": "https://finnhub.io/api/news?id=2ddcc979b64168d6d2b9595c6d33636a28e93546de86932388b4bbbbda5bd717",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759397220,
      "headline": "3 Blue Chip Stocks That Have Soared 380% (and Higher) Over the Past 5 Years",
      "id": 136955191,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "By investing in quality growth stocks, you can put yourself in an excellent position to earn a great return.",
      "url": "https://finnhub.io/api/news?id=2ddcc979b64168d6d2b9595c6d33636a28e93546de86932388b4bbbbda5bd717"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Is Leading The Industry In Cancer Treatments, Says Jim Cramer",
    "summary": "We recently published 5 Stocks That Were On Jim Cramer’s Radar As He Discussed AI. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ) is one of the most diversified healthcare companies in the world. The firm operates in the pharmaceutical, medical devices, and other industries. Cramer […]",
    "url": "https://finnhub.io/api/news?id=d0c816e095f26751096bf1d19a6989f0a42c2d8195125b397ed99e5b4a22d15b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759388914,
      "headline": "Johnson & Johnson (JNJ) Is Leading The Industry In Cancer Treatments, Says Jim Cramer",
      "id": 136955302,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 5 Stocks That Were On Jim Cramer’s Radar As He Discussed AI. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ) is one of the most diversified healthcare companies in the world. The firm operates in the pharmaceutical, medical devices, and other industries. Cramer […]",
      "url": "https://finnhub.io/api/news?id=d0c816e095f26751096bf1d19a6989f0a42c2d8195125b397ed99e5b4a22d15b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Rated Outperform With Strong GLP-1 Prospects",
    "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the stocks with low beta that can beat market volatility. Following the European Association for the Study of Diabetes (EASD) meeting, Bernstein SocGen Group affirmed its Outperform rating on Eli Lilly & Company (NYSE:LLY) with a $1,100 price target. In its analysis, the firm stated that it had […]",
    "url": "https://finnhub.io/api/news?id=1c21a51116a13957b240ce693f2e37a7cfe5d04f19a7a69564975b793407e2da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759385318,
      "headline": "Eli Lilly (LLY) Rated Outperform With Strong GLP-1 Prospects",
      "id": 136955303,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the stocks with low beta that can beat market volatility. Following the European Association for the Study of Diabetes (EASD) meeting, Bernstein SocGen Group affirmed its Outperform rating on Eli Lilly & Company (NYSE:LLY) with a $1,100 price target. In its analysis, the firm stated that it had […]",
      "url": "https://finnhub.io/api/news?id=1c21a51116a13957b240ce693f2e37a7cfe5d04f19a7a69564975b793407e2da"
    }
  }
]